Kirin backs Ireland's FoodMarble in first startup deal from new CVC
What's the deal? KirinDealroom has a profile for this one. Try Dealroom → Holdings has invested in FoodMarble Digestive Health, a Dublin-based digital health startup, through its corporate venture capital arm, Kirin Ventures. The deal, closed on September 30, 2026, is an early-stage round and marks the first startup investment from the newly launched CVC.
What does FoodMarble do? Founded in 2015, the company sells a palm-sized breath-analysis device and companion app. Users breathe into the device, which measures gases produced by fermentation in the gut, letting them track changes at home alongside records of meals and how they feel.
Why now? Self-care tracking is gaining ground, and Japan's "Health Japan 21" plan promotes using apps and wearables for more effective health management. The link between diet and gut health varies from person to person, so Kirin sees breath data as a way to help individuals tailor their eating habits.
What's the endgame? Kirin wants to combine the group's long-standing expertise in gut environment, fermentation, and ingredients with FoodMarble's technology and data. The goal is to explore new value in Japan built around gut health.
FoodMarble sells to consumers mainly in the US and UK, building a continuous record of breath, diet, and condition data. It plans to expand self-care features using that data and AI.
About the backer: Kirin Ventures is the group's CVC brand for startup investment and partnerships. Kirin has run CVC activity since 2020 through vehicles such as the Kirin Health Innovation FundDealroom has a profile for this one. Try Dealroom →, and now aims to widen its scope beyond health science into food, lifestyle, digital, and sustainability. It invests across all stages in Japan, North America, Europe, and Asia.
The signal: Large consumer-goods groups are increasingly pairing their research in fermentation and nutrition with startups selling at-home diagnostics. For Kirin, the FoodMarble deal is a first test of whether its revamped CVC can turn outside technology into new health products.
Read more: prtimes.jp
Image credit: Generated with Gemini